Document Detail

Physicochemical properties of ferumoxytol, a new intravenous iron preparation.
MedLine Citation:
PMID:  19397688     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Intravenous iron is a critical component of anaemia management. However, currently available preparations have been associated with the release of free iron, a promoter of bacterial growth and oxidative stress. MATERIALS AND METHODS: We determined the molecular weight, dialysability and capacity for free iron release of ferumoxytol, a semi-synthetic carbohydrate-coated superparamagnetic iron oxide nanoparticle. Ferumoxytol was compared with three intravenous iron preparations in clinical use: iron dextran (low molecular weight), sodium ferric gluconate and iron sucrose. Intravenous iron preparations were also incubated in rat, and pooled human sera (at concentrations of 600 microM and 42 microg mL(-1) respectively) from healthy subjects. RESULTS: The molecular weight of ferumoxytol was 731 kDa. The relative order of molecular weight was as follows: ferumoxytol > iron dextran > iron sucrose > sodium ferric gluconate. The least ultrafilterable iron was observed with ferumoxytol and the most with ferric gluconate. The least dialysable free iron was observed with ferumoxytol and the most with ferric gluconate. Incubation of intravenous iron preparations in rat or pooled human sera demonstrated minimal free iron release with ferumoxytol. The order of catalytic iron release as detected by the bleomycin detectable iron assay was as follows: ferumoxytol < iron dextran < iron sucrose < ferric gluconate. A similar trend was observed for the in vivo serum concentration of free iron in rats. CONCLUSIONS: In vitro observations from these experiments suggest that ferumoxytol has a favourable profile in terms of tendency to release free iron, in comparison with currently available intravenous iron preparations.
V S Balakrishnan; M Rao; A T Kausz; L Brenner; B J G Pereira; T B Frigo; J M Lewis
Related Documents :
2435698 - Hematologic, iron-related, and acute-phase protein responses to sustained strenuous exe...
4070958 - Preparation of an optically clear frozen human control serum.
7102818 - Hereditary hemochromatosis. analysis of laboratory expression of the disease by genotyp...
17454788 - Nitric oxide affects serum ferritin levels in children with iron deficiency.
7964278 - Manipulation of inhibin during the luteal-follicular phase transition of the primate me...
1422098 - Elevation of plasma atrial natriuretic peptide occurs during adrenaline infusion in hyp...
Publication Detail:
Type:  Journal Article     Date:  2009-04-23
Journal Detail:
Title:  European journal of clinical investigation     Volume:  39     ISSN:  1365-2362     ISO Abbreviation:  Eur. J. Clin. Invest.     Publication Date:  2009 Jun 
Date Detail:
Created Date:  2009-06-03     Completed Date:  2009-12-14     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0245331     Medline TA:  Eur J Clin Invest     Country:  England    
Other Details:
Languages:  eng     Pagination:  489-96     Citation Subset:  IM    
Tufts Medical Center, Boston, MA, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anemia / blood,  drug therapy*
Drug Administration Schedule
Ferrosoferric Oxide / pharmacology*,  therapeutic use
Infusions, Intravenous
Iron-Dextran Complex / pharmacology*
Kidney Failure, Chronic / blood,  drug therapy*
Molecular Weight
Oxidative Stress / drug effects*
Reg. No./Substance:
1317-61-9/Ferrosoferric Oxide; 9004-66-4/Iron-Dextran Complex

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Effect of polymerized-type I collagen in knee osteoarthritis. II. In vivo study.
Next Document:  Serine protease activity of Per a 10 augments allergen-induced airway inflammation in a mouse model.